The Cytomegalovirus (CMV) Infection market growth is driven by factors like increase in the prevalence of Cytomegalovirus ...

Groundbreaking research unveils potential link between cytomegalovirus and Alzheimer's disease, offering new hope for prevention and treatment.

Livtencity (maribavir) has been cleared for use in transplant patients aged 12 or over with CMV infections that do not respond to first-line treatment with current antiviral drugs for CMV ...

The drug has a breakthrough designation from the FDA for refractory CMV infections that are resistant to prior therapy with drugs like ganciclovir, valganciclovir, foscarnet and cidofovir.

It's a concerning possibility, but it also means antiviral drugs might be able to prevent some people from developing ...

The remaining half are used for the treatment of HBV, herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV), influenza and HCV infections. For the antiviral drugs ...

PEP-CMV is under clinical development by Immunomic Therapeutics and currently in Phase I for Anaplastic Astrocytoma.

Cytomegalovirus (CMV), which causes a cold-like illness ... exciting', hope the research could pave the way to confirming ...

A study, which was published in the journal Alzheimer’s & Dementia in December 2024, finds a connection between cytomegalovirus (CMV), a common childhood infection, and Alzheimer’s.

CMV can be injected or delivered intranasally ... “We are applying for two pre-investigational new drugs (INDs): one for our intranasal gene therapy for Alzheimer’s disease and another ...

The treatment of CMVR should start with HAART therapy and systemic oral anti-cytomegalovirus (CMV) therapy, usually valganciclovir. If a patient is diagnosed with CMVR and classified as stage 1 ...